In a randomized controlled trial, Guglin et al. compared lisinopril, carvedilol, and placebo among 468 women with early HER2 positive breast cancer treated with trastuzumab for 12 months, the incidence of cardiotoxicity was 32% in the placebo group vs. 29% and 30% in carvedilol and lisinopril group, respectively, in the rest of the cohort (p=0.002). The gene discussed is ERBB2; the disease is breast cancer.